
Opinion|Videos|January 10, 2025
Assessing New Therapies for Retinal Diseases
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- New Therapies:
- Aflibercept 8 mg
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Timely interventions can protect vision in patients with GA
2
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
3
FLORetina 2025: Long-term follow-up in pediatric gene therapy
4
Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
5







































